Loading…
Solubilization and Interaction of Sulindac with β-Cyclodextrin in the Solid State and in Aqueous Solution
Abstract A sulindac-β-cyclodextrin complex was obtained by the coprecipitation method. Kneaded solids and physical mixtures were also prepared. The complex was shown by x-ray powder diffraction to be noncrystalline whereas pure drug and any of the other sulindac-β-CD system were crystalline. The end...
Saved in:
Published in: | Drug development and industrial pharmacy 1998-01, Vol.24 (3), p.301-306 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c430t-efea8fb1fcbd72a8278d8beb056f61f6508d63a7473c58e8ac5a7ec611bcc0ca3 |
---|---|
cites | cdi_FETCH-LOGICAL-c430t-efea8fb1fcbd72a8278d8beb056f61f6508d63a7473c58e8ac5a7ec611bcc0ca3 |
container_end_page | 306 |
container_issue | 3 |
container_start_page | 301 |
container_title | Drug development and industrial pharmacy |
container_volume | 24 |
creator | Ilarduya, M. C. Tros de Martían, C. Goñi, M. M. Martínez-Ohárriz, M. C. |
description | Abstract
A sulindac-β-cyclodextrin complex was obtained by the coprecipitation method. Kneaded solids and physical mixtures were also prepared. The complex was shown by x-ray powder diffraction to be noncrystalline whereas pure drug and any of the other sulindac-β-CD system were crystalline. The endothermic peak of sulindac due to the fusion of drug disappeared in DSC thermograms for the coprecipitate product, which confirmed the interaction between sulindac and β-CD in the solid state. After a 1-year storage drug crystals could not be observed by x-ray diffractometry, which indicated that the complex formed was stable. The complex showed the fastest dissolution rate which might be attributed to the high-energy noncrystalline state and the inclusion complex formation in solution. UV spectra were modified and the apparent solubility of the drug increased with the addition of β-CD, which confirmed the interaction between sulindac and the ligand in solution. The apparent stability constant, K1:1, for the complex at pH 2 and 25, 30, and 37°C was 340, 220, and 160 M−1, respectively, which confirmed the influence of temperature on the complex stability. The value of K1:1 at pH 6 and 25°C was 139 M−1, which indicated that the complex is formed easier with the non-ionized sulindac. The enthalpy change, δH°, showed that the binding process is exothermic. |
doi_str_mv | 10.3109/03639049809085624 |
format | article |
fullrecord | <record><control><sourceid>pubmed_infor</sourceid><recordid>TN_cdi_informahealthcare_journals_10_3109_03639049809085624</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9876589</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-efea8fb1fcbd72a8278d8beb056f61f6508d63a7473c58e8ac5a7ec611bcc0ca3</originalsourceid><addsrcrecordid>eNp9kMtKAzEYhYMotV4ewIUwC7ejyaTJZNCNFC-FgovqevgnF5qSTmomQ62P5YP4TE5tFUQoBH6Sc75D_oPQGcGXlODiClNOCzwoBC6wYDwb7KE-YRlOWc6zfdRf62lnYIfoqGlmGJOsYKyHeoXIORNFH80m3rWVdfYdovV1ArVKRnXUAeT33Ztk0jpbK5DJ0sZp8vmRDlfSeaXfYrB10p041UkXY1UyiRD1d0b3fPvaat82a6ldZ52gAwOu0afbeYxe7u-eh4_p-OlhNLwdp3JAcUy10SBMRYysVJ6ByHKhRKUrzLjhxHCGheIU8kFOJRNagGSQa8kJqaTEEugxIptcGXzTBG3KRbBzCKuS4HJdW_mvto453zCLtppr9Utse-r0i60OjQRnAtTSNr-2jIiCUNbZbjY2Wxsf5rD0wakywsr58MPQXb-4_oNPNbg4lRB0OfNtqLvWduzwBScznRc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Solubilization and Interaction of Sulindac with β-Cyclodextrin in the Solid State and in Aqueous Solution</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Ilarduya, M. C. Tros de ; Martían, C. ; Goñi, M. M. ; Martínez-Ohárriz, M. C.</creator><creatorcontrib>Ilarduya, M. C. Tros de ; Martían, C. ; Goñi, M. M. ; Martínez-Ohárriz, M. C.</creatorcontrib><description>Abstract
A sulindac-β-cyclodextrin complex was obtained by the coprecipitation method. Kneaded solids and physical mixtures were also prepared. The complex was shown by x-ray powder diffraction to be noncrystalline whereas pure drug and any of the other sulindac-β-CD system were crystalline. The endothermic peak of sulindac due to the fusion of drug disappeared in DSC thermograms for the coprecipitate product, which confirmed the interaction between sulindac and β-CD in the solid state. After a 1-year storage drug crystals could not be observed by x-ray diffractometry, which indicated that the complex formed was stable. The complex showed the fastest dissolution rate which might be attributed to the high-energy noncrystalline state and the inclusion complex formation in solution. UV spectra were modified and the apparent solubility of the drug increased with the addition of β-CD, which confirmed the interaction between sulindac and the ligand in solution. The apparent stability constant, K1:1, for the complex at pH 2 and 25, 30, and 37°C was 340, 220, and 160 M−1, respectively, which confirmed the influence of temperature on the complex stability. The value of K1:1 at pH 6 and 25°C was 139 M−1, which indicated that the complex is formed easier with the non-ionized sulindac. The enthalpy change, δH°, showed that the binding process is exothermic.</description><identifier>ISSN: 0363-9045</identifier><identifier>EISSN: 1520-5762</identifier><identifier>DOI: 10.3109/03639049809085624</identifier><identifier>PMID: 9876589</identifier><language>eng</language><publisher>Colchester: Informa UK Ltd</publisher><subject>beta-Cyclodextrins ; Biological and medical sciences ; Bones, joints and connective tissue. Antiinflammatory agents ; Chemical Phenomena ; Chemistry, Physical ; Cyclodextrins ; Medical sciences ; Pharmacology. Drug treatments ; Solubility ; Solutions ; Spectrophotometry, Ultraviolet ; Sulindac - chemistry ; X-Ray Diffraction</subject><ispartof>Drug development and industrial pharmacy, 1998-01, Vol.24 (3), p.301-306</ispartof><rights>1998 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1998</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-efea8fb1fcbd72a8278d8beb056f61f6508d63a7473c58e8ac5a7ec611bcc0ca3</citedby><cites>FETCH-LOGICAL-c430t-efea8fb1fcbd72a8278d8beb056f61f6508d63a7473c58e8ac5a7ec611bcc0ca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2189135$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9876589$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ilarduya, M. C. Tros de</creatorcontrib><creatorcontrib>Martían, C.</creatorcontrib><creatorcontrib>Goñi, M. M.</creatorcontrib><creatorcontrib>Martínez-Ohárriz, M. C.</creatorcontrib><title>Solubilization and Interaction of Sulindac with β-Cyclodextrin in the Solid State and in Aqueous Solution</title><title>Drug development and industrial pharmacy</title><addtitle>Drug Dev Ind Pharm</addtitle><description>Abstract
A sulindac-β-cyclodextrin complex was obtained by the coprecipitation method. Kneaded solids and physical mixtures were also prepared. The complex was shown by x-ray powder diffraction to be noncrystalline whereas pure drug and any of the other sulindac-β-CD system were crystalline. The endothermic peak of sulindac due to the fusion of drug disappeared in DSC thermograms for the coprecipitate product, which confirmed the interaction between sulindac and β-CD in the solid state. After a 1-year storage drug crystals could not be observed by x-ray diffractometry, which indicated that the complex formed was stable. The complex showed the fastest dissolution rate which might be attributed to the high-energy noncrystalline state and the inclusion complex formation in solution. UV spectra were modified and the apparent solubility of the drug increased with the addition of β-CD, which confirmed the interaction between sulindac and the ligand in solution. The apparent stability constant, K1:1, for the complex at pH 2 and 25, 30, and 37°C was 340, 220, and 160 M−1, respectively, which confirmed the influence of temperature on the complex stability. The value of K1:1 at pH 6 and 25°C was 139 M−1, which indicated that the complex is formed easier with the non-ionized sulindac. The enthalpy change, δH°, showed that the binding process is exothermic.</description><subject>beta-Cyclodextrins</subject><subject>Biological and medical sciences</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Chemical Phenomena</subject><subject>Chemistry, Physical</subject><subject>Cyclodextrins</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Solubility</subject><subject>Solutions</subject><subject>Spectrophotometry, Ultraviolet</subject><subject>Sulindac - chemistry</subject><subject>X-Ray Diffraction</subject><issn>0363-9045</issn><issn>1520-5762</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNp9kMtKAzEYhYMotV4ewIUwC7ejyaTJZNCNFC-FgovqevgnF5qSTmomQ62P5YP4TE5tFUQoBH6Sc75D_oPQGcGXlODiClNOCzwoBC6wYDwb7KE-YRlOWc6zfdRf62lnYIfoqGlmGJOsYKyHeoXIORNFH80m3rWVdfYdovV1ArVKRnXUAeT33Ztk0jpbK5DJ0sZp8vmRDlfSeaXfYrB10p041UkXY1UyiRD1d0b3fPvaat82a6ldZ52gAwOu0afbeYxe7u-eh4_p-OlhNLwdp3JAcUy10SBMRYysVJ6ByHKhRKUrzLjhxHCGheIU8kFOJRNagGSQa8kJqaTEEugxIptcGXzTBG3KRbBzCKuS4HJdW_mvto453zCLtppr9Utse-r0i60OjQRnAtTSNr-2jIiCUNbZbjY2Wxsf5rD0wakywsr58MPQXb-4_oNPNbg4lRB0OfNtqLvWduzwBScznRc</recordid><startdate>19980101</startdate><enddate>19980101</enddate><creator>Ilarduya, M. C. Tros de</creator><creator>Martían, C.</creator><creator>Goñi, M. M.</creator><creator>Martínez-Ohárriz, M. C.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19980101</creationdate><title>Solubilization and Interaction of Sulindac with β-Cyclodextrin in the Solid State and in Aqueous Solution</title><author>Ilarduya, M. C. Tros de ; Martían, C. ; Goñi, M. M. ; Martínez-Ohárriz, M. C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-efea8fb1fcbd72a8278d8beb056f61f6508d63a7473c58e8ac5a7ec611bcc0ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>beta-Cyclodextrins</topic><topic>Biological and medical sciences</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Chemical Phenomena</topic><topic>Chemistry, Physical</topic><topic>Cyclodextrins</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Solubility</topic><topic>Solutions</topic><topic>Spectrophotometry, Ultraviolet</topic><topic>Sulindac - chemistry</topic><topic>X-Ray Diffraction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ilarduya, M. C. Tros de</creatorcontrib><creatorcontrib>Martían, C.</creatorcontrib><creatorcontrib>Goñi, M. M.</creatorcontrib><creatorcontrib>Martínez-Ohárriz, M. C.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Drug development and industrial pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ilarduya, M. C. Tros de</au><au>Martían, C.</au><au>Goñi, M. M.</au><au>Martínez-Ohárriz, M. C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Solubilization and Interaction of Sulindac with β-Cyclodextrin in the Solid State and in Aqueous Solution</atitle><jtitle>Drug development and industrial pharmacy</jtitle><addtitle>Drug Dev Ind Pharm</addtitle><date>1998-01-01</date><risdate>1998</risdate><volume>24</volume><issue>3</issue><spage>301</spage><epage>306</epage><pages>301-306</pages><issn>0363-9045</issn><eissn>1520-5762</eissn><abstract>Abstract
A sulindac-β-cyclodextrin complex was obtained by the coprecipitation method. Kneaded solids and physical mixtures were also prepared. The complex was shown by x-ray powder diffraction to be noncrystalline whereas pure drug and any of the other sulindac-β-CD system were crystalline. The endothermic peak of sulindac due to the fusion of drug disappeared in DSC thermograms for the coprecipitate product, which confirmed the interaction between sulindac and β-CD in the solid state. After a 1-year storage drug crystals could not be observed by x-ray diffractometry, which indicated that the complex formed was stable. The complex showed the fastest dissolution rate which might be attributed to the high-energy noncrystalline state and the inclusion complex formation in solution. UV spectra were modified and the apparent solubility of the drug increased with the addition of β-CD, which confirmed the interaction between sulindac and the ligand in solution. The apparent stability constant, K1:1, for the complex at pH 2 and 25, 30, and 37°C was 340, 220, and 160 M−1, respectively, which confirmed the influence of temperature on the complex stability. The value of K1:1 at pH 6 and 25°C was 139 M−1, which indicated that the complex is formed easier with the non-ionized sulindac. The enthalpy change, δH°, showed that the binding process is exothermic.</abstract><cop>Colchester</cop><pub>Informa UK Ltd</pub><pmid>9876589</pmid><doi>10.3109/03639049809085624</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0363-9045 |
ispartof | Drug development and industrial pharmacy, 1998-01, Vol.24 (3), p.301-306 |
issn | 0363-9045 1520-5762 |
language | eng |
recordid | cdi_informahealthcare_journals_10_3109_03639049809085624 |
source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
subjects | beta-Cyclodextrins Biological and medical sciences Bones, joints and connective tissue. Antiinflammatory agents Chemical Phenomena Chemistry, Physical Cyclodextrins Medical sciences Pharmacology. Drug treatments Solubility Solutions Spectrophotometry, Ultraviolet Sulindac - chemistry X-Ray Diffraction |
title | Solubilization and Interaction of Sulindac with β-Cyclodextrin in the Solid State and in Aqueous Solution |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T14%3A01%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Solubilization%20and%20Interaction%20of%20Sulindac%20with%20%CE%B2-Cyclodextrin%20in%20the%20Solid%20State%20and%20in%20Aqueous%20Solution&rft.jtitle=Drug%20development%20and%20industrial%20pharmacy&rft.au=Ilarduya,%20M.%20C.%20Tros%20de&rft.date=1998-01-01&rft.volume=24&rft.issue=3&rft.spage=301&rft.epage=306&rft.pages=301-306&rft.issn=0363-9045&rft.eissn=1520-5762&rft_id=info:doi/10.3109/03639049809085624&rft_dat=%3Cpubmed_infor%3E9876589%3C/pubmed_infor%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c430t-efea8fb1fcbd72a8278d8beb056f61f6508d63a7473c58e8ac5a7ec611bcc0ca3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/9876589&rfr_iscdi=true |